EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Addressing therapeutic options for KPC-3-producing ST307- Klebsiella pneumoniae : insights from in vitro evolution and mutant prevention strategies

Marta Hernández-García iD, Blanca Pérez-Viso iD, Marta Nieto-Torres, María García-Castillo, Malkoa Michelena, Luis Martínez-Martínez iD, Fernando Baquero iD, Patricia Ruiz-Garbajosa iD, Rafael Cantón iD

Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)

DOI: 10.1128/aac.00488-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Marta Hernández-García und 8 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FiBIO-IRYCIS, Instituto Salud Carlos III, CIBER, CIBERINFEC (CB21/13/00084).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are key therapeutic options for infections caused by KPC-producing Klebsiella pneumoniae (KPC-Kp). Resistance may emerge during therapy, but knowledge on mutant prevention and collateral effects remains limited. Killing kinetics assays of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, and the combination of ceftazidime-avibactam with meropenem (CZA + MER) were performed against clinical KPC-3-ST307-Kp isolates and ceftazidime-avibactam-resistant KPC-ST307-Kp mutants (KPC-31/KPC-46/KPC-53/KPC-61/KPC-62/KPC-66/KPC-92/KPC-150-Kp) with different genetic backgrounds. Single-step mutant frequencies and resistance trajectories were established. WGS was used to identify resistance mechanisms, and collateral resistance to other last-line agents was assessed. In time-kill assays, meropenem and ceftazidime-avibactam showed bactericidal activity at high concentrations (2× MIC and 4× MIC). Meropenem-vaborbactam was bactericidal only at high exposures (2× MIC and 4× MIC) and with reduced activity in porin-deficient strains, whereas imipenem-relebactam was bactericidal in half of the strains at 4× MIC. CZA + MER showed synergistic bactericidal activity across all KPC-Kp isolates, even at subinhibitory concentrations. CZA + MER completely suppressed the emergence of resistant mutants (mutation rate

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaeAnti-Bacterial Agentsbeta-LactamasesCeftazidimeAzabicyclo CompoundsImipenemMicrobial Sensitivity TestsDrug CombinationsBoronic AcidsMeropenemMutationDrug Resistance, Multiple, BacterialKlebsiella InfectionsHumansThienamycinsNucleosidesBacterial ProteinsHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

KPC-ST307-K. pneumoniaeceftazidime-avibactamcollateral sensitivity to carbapenemsimipenem-relebactammeropenem-vaborbactam

Substanzen

Anti-Bacterial AgentsCeftazidimeAzabicyclo CompoundsImipenemDrug CombinationsBoronic Acidsavibactam, ceftazidime drug combinationbeta-LactamasesMeropenembeta-lactamase KPC-3, Klebsiella pneumoniae

Autor:innen und Institutionen

  • Servicio de Microbiología, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto Salud Carlos III (ISCIII), Madrid, Spain.
  • Unidad de Microbiología, Hospital Universitario Reina Sofia, Córdoba, Spain.
  • Departamento de Química Agrícola, Edafología y Microbiología, Universidad de Córdoba, Córdoba, Spain.
  • Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain.

ORCID-Profile: Marta Hernández-García, Blanca Pérez-Viso, Luis Martínez-Martínez, Fernando Baquero, Patricia Ruiz-Garbajosa, Rafael Cantón

Förderung

  • FiBIO-IRYCIS
  • Instituto Salud Carlos III, CIBER
  • CIBERINFEC (CB21/13/00084)
  • Instituto Salud Carlos III, AES 2022
  • Instituto Salud Carlos III, AES 2024

Zitieren

APA

Hernández-García, M., Pérez-Viso, B., Nieto-Torres, M., García-Castillo, M., Michelena, M., Martínez-Martínez, L., Baquero, F., Ruiz-Garbajosa, P., & Cantón, R. (2026). Addressing therapeutic options for KPC-3-producing ST307- Klebsiella pneumoniae : insights from in vitro evolution and mutant prevention strategies. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00488-26

Vancouver

Hernández-García M, Pérez-Viso B, Nieto-Torres M, García-Castillo M, Michelena M, Martínez-Martínez L, et al. Addressing therapeutic options for KPC-3-producing ST307- Klebsiella pneumoniae : insights from in vitro evolution and mutant prevention strategies. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00488-26

BibTeX
@article{HernndezGarca2026,
  author = {Hernández-García, Marta and Pérez-Viso, Blanca and Nieto-Torres, Marta and García-Castillo, María and Michelena, Malkoa and Martínez-Martínez, Luis and Baquero, Fernando and Ruiz-Garbajosa, Patricia and Cantón, Rafael},
  title = {Addressing therapeutic options for KPC-3-producing ST307- Klebsiella pneumoniae : insights from in vitro evolution and mutant prevention strategies},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {8},
  doi = {10.1128/aac.00488-26}
}
Kostenlos starten →